Akero Therapeutics (AKRO) Competitors $51.52 -0.25 (-0.48%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO vs. SMMT, ITCI, GMAB, RDY, QGEN, VTRS, ASND, MRNA, BBIO, and BPMCShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Akero Therapeutics vs. Its Competitors Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S Moderna BridgeBio Pharma Blueprint Medicines Akero Therapeutics (NASDAQ:AKRO) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Do analysts prefer AKRO or SMMT? Akero Therapeutics currently has a consensus price target of $82.50, suggesting a potential upside of 60.13%. Summit Therapeutics has a consensus price target of $34.67, suggesting a potential upside of 53.32%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Akero Therapeutics is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79 Which has more risk and volatility, AKRO or SMMT? Akero Therapeutics has a beta of -0.15, meaning that its share price is 115% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.01, meaning that its share price is 201% less volatile than the S&P 500. Is AKRO or SMMT more profitable? Akero Therapeutics' return on equity of -15.19% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.19% -13.97% Summit Therapeutics N/A -62.87%-51.61% Which has stronger earnings and valuation, AKRO or SMMT? Summit Therapeutics has higher revenue and earnings than Akero Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$1.95-26.42Summit Therapeutics$700K23,988.24-$221.32M-$0.34-66.50 Does the media refer more to AKRO or SMMT? In the previous week, Summit Therapeutics had 17 more articles in the media than Akero Therapeutics. MarketBeat recorded 21 mentions for Summit Therapeutics and 4 mentions for Akero Therapeutics. Summit Therapeutics' average media sentiment score of 0.47 beat Akero Therapeutics' score of 0.33 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of AKRO or SMMT? 4.6% of Summit Therapeutics shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummarySummit Therapeutics beats Akero Therapeutics on 9 of the 15 factors compared between the two stocks. Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.13B$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-26.4220.3027.1920.03Price / SalesN/A251.54414.39108.98Price / CashN/A41.7026.2128.59Price / Book4.797.397.925.55Net Income-$252.06M-$55.04M$3.17B$248.49M7 Day Performance-3.45%3.01%2.18%5.37%1 Month Performance-5.08%-0.21%1.25%6.63%1 Year Performance140.19%4.48%33.90%21.20% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics3.4204 of 5 stars$51.52-0.5%$82.50+60.1%+142.5%$4.13BN/A-26.4230SMMTSummit Therapeutics2.4602 of 5 stars$21.28+3.3%$35.09+64.9%+236.3%$15.30B$700K-62.59110ITCIIntra-Cellular Therapies0.9246 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8379 of 5 stars$20.66+0.8%$37.60+82.0%-20.1%$13.15B$3.12B11.742,682RDYDr. Reddy's Laboratories2.6782 of 5 stars$15.03-0.3%$16.95+12.8%-3.4%$12.58B$3.81B22.7727,811QGENQiagen3.8493 of 5 stars$48.07+0.6%$49.40+2.8%+21.0%$10.62B$1.98B120.525,765Dividend AnnouncementVTRSViatris3.3418 of 5 stars$8.93-0.9%$10.40+16.5%-10.4%$10.57B$14.74B-2.8232,000ASNDAscendis Pharma A/S3.458 of 5 stars$172.60+0.2%$220.67+27.8%+28.2%$10.53B$393.54M-27.481,017MRNAModerna4.36 of 5 stars$27.59+1.6%$46.61+68.9%-74.2%$10.50B$3.24B-3.165,800BBIOBridgeBio Pharma4.673 of 5 stars$43.18-3.7%$58.85+36.3%+69.7%$8.52B$221.90M-12.23400High Trading VolumeBPMCBlueprint Medicines1.3655 of 5 stars$128.18+0.1%$128.06-0.1%+14.8%$8.27B$508.82M-51.89640Positive News Related Companies and Tools Related Companies Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Qiagen Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKRO) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
